Tests REC-1245 in people with cancers that cannot be removed by surgery
Tests the oral drug REC-1245 in people with advanced solid tumors or lymphomas.
Plain-language title generated from the registry record
Registry title: A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Key facts
- Where
- Québec and Toronto, CanadaSee the 2 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 12 and older with certain solid tumors or lymphomas that cannot be removed by surgery, have spread, or have come back. They must have already tried standard treatment.
- Age
- 12 years and older
- Sex
- All sexes can join
- Disease stage
- Selected solid tumors or lymphomas that cannot be removed by surgery, are locally advanced or have spread, or have relapsed or not responded to treatment. The disease must be measurable on CT or MRI scans.
- Earlier treatment
- Must have had disease that got worse, came back, or could not be tolerated on at least one standard cancer drug treatment, or be considered unable to have standard therapy. Must not have had treatment with another RBM39 degrader.
Main reasons for not taking part
- Treatment with another RBM39 degrader
- Clinically significant stomach or bowel problems, or problems absorbing food and medicines from the gut
Read by machine on 12 November 2026.
Where in Canada
- McGill University Health Centre (MUHC) - The MontrealQuébec, CanadaContact: Phuong-nam NguyenTaking people
- Princess Margaret Cancer CentreToronto, CanadaContact: Anh NguyenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Recursion Pharmaceuticals Inc.
- Trial code
- NCT06678659
- Record updated
- 20 August 2026
- Original description
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.Read full original descriptionShow less
A Phase 1 / 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.
Inclusion: Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma; Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy; Eastern cooperative oncology group (ECOG) performance status ≤1; for adolescent participants, Lansky Performance Status Scale or Karnofsky Performance Status Scale score of ≥70; Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 / Lugano criteria and documented by computed tomography (CT) and / or magnetic resonance imaging (MRI).
Exclusion: Received treatment with another RBM39 degrader; Clinically significant gastrointestinal (GI) or GI malabsorption.